News archive
Key Steps to Get Your IND Schedule on Track
Preparing for an Investigational New Drug (IND) application represents a key milestone for First-In-Human (FIH) studies. For many drug developers, especially those newer to the field, navigating this process can be complex. To simplify this journey, we dive into the...
Scantox closes the acquisition of QPS Neuropharmacology – now Scantox Neuro
2 April 2024 -- Today Scantox, together with its majority owner Impilo, finalized the acquisition of QPS Neuropharmacology, a leading drug discovery CRO specialized in neurodegenerative, rare diseases and mental disorders. The company, as of today integrated into the...
Visit Scantox at SOT in Salt Lake City: Discover Expanded Service Offerings and Collaborative Atmosphere
As the Society of Toxicology (SOT) Annual Meeting approaches, biopharmaceutical companies have a prime opportunity to engage with industry leaders and explore innovative solutions to advance drug development initiatives. This year, the team at Scantox extends a warm...
Scantox acquires QPS Austria’s Neuropharmacology Division
30th November 2023 -- Today Scantox, together with its majority owner Impilo, has agreed to acquire the neuropharmacology division of QPS Austria GmbH (“QPS Neuro” or “the Company”) ultimately owned by QPS Holdings LLC. QPS Neuro is a leading drug discovery Contract...
Scantox continues its growth journey with the acquisition of Solural Pharma
Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo. Solural has strong...
Scantox appoints Morten Fjordholt as Sr. Business Development Director
November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships...
Scantox acquires Q&Q – strengthening its offering within bioanalytical services
31 August 2023 -- Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisition of Q&Q Labs AB located...
Scantox appoints Andy Brown as Group Chief Commercial Officer
July 7th – Scantox Group, a leading provider of nonclinical services in Europe, has named Andy Brown as Group Chief Commercial Officer with the overall responsibility of growing sales within toxicology, discovery and lab services and fostering positive relationships...
Exclusive genOway distributors in the Nordics
Scantox is pleased to announce that we are exclusive distributors of advanced preclinical models, including the BRGSF-HIS and advanced humanized immune checkpoint models from genOway in Demark, Sweden, Norway and Finland. The genOway BRGSF-HIS mouse possesses the most...
Scantox Certified as 2023 Great Place to Work
Scantox is proud to be certified by Great Place to Work™. This prestigious award is based entirely on what current employees say about their experience of working at Scantox. It takes an entire team of dedicated individuals to achieve what we do at Scantox. Each...